Last updated: November 4, 2026
LO/Ovral-28 is a legacy combined oral contraceptive containing norgestrel 0.3 mg and ethinyl estradiol 0.03 mg. The product was originally commercialized by Wyeth and later held by Pfizer after Pfizer’s acquisition of Wyeth. Its commercial value declined after generic equivalents entered the market, and no reliable public source reports standalone revenue for LO/Ovral-28. The product’s economic profile is now that of a discontinued or commercially inactive branded contraceptive rather than a protected pharmaceutical asset.
What is LO/Ovral-28 and how does it work?
LO/Ovral-28 is a 28-tablet oral contraceptive regimen containing:
| Attribute |
LO/Ovral-28 |
| Active ingredients |
Norgestrel 0.3 mg and ethinyl estradiol 0.03 mg |
| Dosage form |
Oral tablet |
| Pack structure |
21 active tablets and 7 inactive tablets |
| Therapeutic class |
Combined hormonal contraceptive |
| Primary indication |
Prevention of pregnancy |
| Original sponsor |
Wyeth-Ayerst Laboratories |
| Later corporate owner |
Pfizer |
| Reference NDA |
NDA 018035, as identified in FDA product records |
| Current commercial position |
Legacy product with no meaningful branded franchise evidence in current public reporting |
Norgestrel is a progestin and ethinyl estradiol is an estrogen. The combination suppresses ovulation and produces contraceptive effects through changes in cervical mucus and the endometrium. The FDA-approved labeling also identifies estrogen-related thromboembolic and cardiovascular risks and contraindications for specific patient populations (U.S. Food and Drug Administration [FDA], n.d.-a).
When did LO/Ovral-28 lose exclusivity?
LO/Ovral-28 lost meaningful market exclusivity decades ago. The product is an older small-molecule oral contraceptive, and generic versions of the norgestrel/ethinyl estradiol formulation became available well before the current patent and regulatory environment.
The relevant commercial protection was not a currently enforceable patent estate. Product-specific protection consisted primarily of:
- Expired composition and formulation patents, if any were listed historically.
- Expired regulatory exclusivity associated with the original NDA.
- Trademark and brand recognition, which did not prevent ANDA-based generic competition.
- Manufacturing and supply arrangements that had limited strategic value after generic entry.
The FDA Orange Book distinguishes between listed patents and discontinued products. A product’s appearance in historical FDA records does not establish that its patents remain enforceable or that the branded product remains commercially active (FDA, n.d.-b).
Was LO/Ovral-28 protected by active patents?
No active, commercially material patent protection is apparent from the product’s age and historical generic competition. The underlying active ingredients are long-established molecules, and the conventional tablet formulation does not present a current patent barrier comparable to a new molecular entity, complex formulation, implant, injectable, or biologic.
Any historical patent listings associated with the original NDA would have expired by the time generic norgestrel/ethinyl estradiol products were widely marketed. The principal commercial risk shifted from patent litigation to ordinary generic price competition.
What generic products compete with LO/Ovral-28?
LO/Ovral-28 competed with generic products containing the same active ingredients and strengths. Common U.S. market names historically included:
| Product |
Active ingredients |
Market role |
| LO/Ovral-28 |
Norgestrel 0.3 mg / ethinyl estradiol 0.03 mg |
Original branded product |
| Cryselle-28 |
Norgestrel 0.3 mg / ethinyl estradiol 0.03 mg |
Generic or multisource equivalent |
| Low-Ogestrel |
Norgestrel 0.3 mg / ethinyl estradiol 0.03 mg |
Branded-generic or generic competitor |
| Elinest |
Norgestrel 0.3 mg / ethinyl estradiol 0.03 mg |
Generic competitor |
Product availability has varied by manufacturer, wholesaler, pharmacy channel, and time period. The formulation also competes indirectly with levonorgestrel/ethinyl estradiol oral contraceptives, progestin-only pills, contraceptive patches, vaginal rings, injectables, intrauterine systems, implants, and over-the-counter emergency contraception.
What was the commercial effect of generic entry?
Generic entry likely caused the standard revenue trajectory for an older oral contraceptive:
- Initial branded sales supported by physician prescribing and brand familiarity.
- Rapid substitution after ANDA approvals.
- Declining branded prescription volume as payers and pharmacy benefit managers favored lower-cost equivalents.
- Reduced promotional spending and lower wholesale demand.
- Product withdrawal, discontinuation, or marginal availability after the brand no longer justified commercial support.
Unlike specialty drugs, LO/Ovral-28 had limited opportunities for premium pricing. Its active ingredients were well known, the dosage form was simple, and therapeutic substitution was extensive. The product therefore had weak long-term pricing power.
What is known about LO/Ovral-28 revenue?
No reliable public filing identifies standalone LO/Ovral-28 revenue. Wyeth and Pfizer reported pharmaceutical sales at business-segment or portfolio levels rather than at the individual product level. Public company filings therefore cannot support a defensible annual revenue series for this product.
| Financial metric |
Publicly supportable conclusion |
| Peak annual revenue |
Not separately disclosed |
| Current annual revenue |
No reliable standalone figure identified |
| Gross margin |
Not disclosed |
| Marketing expense |
Not disclosed |
| Generic erosion rate |
Not disclosed for this product |
| Licensing income |
No material product-specific licensing stream publicly established |
| Current franchise value |
Low or negligible as an independent branded asset |
The financial trajectory can be assessed directionally, but not quantified without proprietary prescription, shipment, or claims data. By the time Pfizer controlled the product, LO/Ovral-28 was part of a mature contraceptive portfolio rather than a growth product.
Did the 2012 Pfizer recall affect LO/Ovral-28?
Yes. Pfizer recalled certain lots of LO/Ovral-28 and generic norgestrel/ethinyl estradiol tablets in 2012 after packaging errors could result in tablets being placed in the incorrect sequence or missing from blister packs. The recall affected contraception reliability because the pack’s order determines when active and inactive tablets are taken.
The FDA reported that the packaging issue could expose patients to an unintended risk of pregnancy. Pfizer advised patients to continue taking tablets according to the prescribed schedule and to use backup contraception where appropriate (FDA, 2012; Pfizer, 2012).
The recall had four likely commercial effects:
- Temporary channel disruption.
- Additional manufacturing and quality-control costs.
- Loss of confidence among prescribers and patients.
- Greater substitution toward alternative oral contraceptives.
The recall was a product-quality event, not a patent or exclusivity event. Its effect on long-term revenue cannot be isolated from the broader decline caused by generic competition and portfolio rationalization.
What is the FDA regulatory status of LO/Ovral-28?
LO/Ovral-28 was approved through the FDA new drug application pathway. Its active ingredients and dosage form are conventional and do not require biologic licensing or biosimilar review.
Does LO/Ovral-28 have biosimilar risk?
No. Biosimilars apply to biological products, not conventional combined oral contraceptive tablets. The relevant competitive pathway was the abbreviated new drug application, or ANDA, for generic equivalents.
What is the Orange Book status of LO/Ovral-28?
The product is associated with historical FDA Orange Book and NDA records. A product marked discontinued in FDA records is not necessarily withdrawn for safety reasons. Discontinuation can reflect commercial withdrawal, manufacturing decisions, supply issues, or replacement by generic products.
The commercial significance is limited: an old oral contraceptive with no current market exclusivity does not obtain renewed protection merely because the reference product remains in historical FDA databases.
Were there Paragraph IV challenges to LO/Ovral-28?
Generic applicants could have used Paragraph IV certifications against any unexpired listed patents when filing ANDAs. However, no current, material Paragraph IV litigation risk is apparent for LO/Ovral-28.
The product’s age makes a prolonged patent challenge unlikely today. Any relevant patents would generally have expired before the current period, and the market has long included generic equivalents. The key distinction is:
| Issue |
LO/Ovral-28 assessment |
| Current Paragraph IV threat |
Low |
| Patent litigation value |
Low |
| Generic substitution |
Established |
| Regulatory exclusivity |
Expired |
| Biosimilar exposure |
Not applicable |
| Re-launch protection |
None apparent without a new patentable innovation |
What formulation patents protect LO/Ovral-28?
No commercially important active formulation patent is apparent for the conventional LO/Ovral-28 tablet. The product does not rely on an extended-release system, transdermal delivery platform, implant, depot injection, or device-linked delivery technology.
Potential technical protections historically could have covered:
- Tablet composition.
- Compression and manufacturing parameters.
- Packaging configuration.
- Stability characteristics.
- Dosing regimen.
Those categories do not create a durable barrier when the formulation is old and generic equivalents are approved. Packaging or manufacturing know-how may protect quality and supply performance internally, but it does not generally block an ANDA competitor from marketing an equivalent product.
How strong is the patent estate for LO/Ovral-28?
The patent estate is weak from an investment or licensing perspective.
| Patent-estate factor |
Assessment |
| Active ingredient patents |
Expired |
| Core formulation protection |
Expired or commercially immaterial |
| Method-of-use patents |
No material current protection identified |
| Manufacturing patents |
Limited strategic value |
| Device or delivery protection |
None material |
| Orange Book leverage |
Low |
| Generic blocking ability |
None apparent |
| Licensing value |
Low |
A commercial relaunch would need a new differentiator, such as a novel delivery system, improved tolerability profile, new indication, patient-specific dosing platform, or combination with a proprietary technology. The legacy product itself does not provide a defensible basis for premium pricing.
What patent litigation or settlement agreements affect LO/Ovral-28?
No active patent litigation or enforceable settlement arrangement is central to the current LO/Ovral-28 market. The product’s competitive history is primarily one of generic substitution and supply management.
The 2012 recall involved quality and packaging issues, not a patent dispute. Publicly visible commercial agreements associated with Pfizer’s broader contraceptive portfolio do not establish an ongoing licensing stream specific to LO/Ovral-28.
How does LO/Ovral-28 compare with newer contraceptives?
LO/Ovral-28 has a low commercial and IP profile compared with newer contraceptive products.
| Product category |
Patent strength |
Pricing power |
Generic or biosimilar exposure |
Commercial outlook |
| LO/Ovral-28 legacy tablet |
Low |
Low |
High generic exposure |
Mature or inactive |
| New branded oral contraceptive |
Variable |
Moderate |
Future generic risk |
Depends on differentiation |
| Vaginal ring |
Moderate if technology is protected |
Moderate |
Product-specific |
Higher technical complexity |
| Hormonal IUD |
Higher device and formulation complexity |
Higher |
Limited direct substitution |
Durable franchise potential |
| Implant |
Device and manufacturing protection |
Moderate to high |
Limited |
Specialist and procedural market |
| Biologic contraceptive platform |
Potentially high |
High |
Biosimilar risk |
Not comparable to LO/Ovral-28 |
The main substitute risk is not another patent-protected oral contraceptive. It is patient and prescriber movement across contraceptive modalities, including long-acting reversible contraception.
What generic launch scenarios exist for LO/Ovral-28?
The realistic market scenarios are:
Continued generic availability
Multiple manufacturers maintain low-cost versions, with periodic supply interruptions caused by active pharmaceutical ingredient sourcing, manufacturing capacity, or wholesaler decisions.
Brand disappearance with therapeutic substitution
The branded product remains absent while pharmacies dispense generic norgestrel/ethinyl estradiol or a therapeutically similar contraceptive.
Limited reintroduction
A distributor or manufacturer reintroduces the brand for niche demand, but without patent protection. Such a launch would face immediate generic and payer pressure.
Reformulated relaunch
A reformulated product could obtain new patents only if the change meets patentability standards and supports a distinct clinical or commercial benefit. A simple relabeling or conventional dosage adjustment would not create durable exclusivity.
What are the geographic market dynamics?
LO/Ovral-28’s commercial history is primarily associated with the U.S. market, where FDA approval, Orange Book listings, managed-care substitution, and ANDA competition determined its position.
Outside the United States, equivalent products may have been marketed under different names, regulatory approvals, or manufacturer arrangements. International rights, trademarks, and product availability cannot be treated as identical to U.S. rights. The active ingredients are widely available, which limits geographic patent leverage unless a specific jurisdiction had a surviving formulation, use, or process patent.
Key Takeaways
- LO/Ovral-28 is an older combined oral contraceptive containing norgestrel and ethinyl estradiol.
- Its meaningful market exclusivity expired long ago.
- Generic equivalents, including Cryselle-28, Low-Ogestrel, and Elinest, eroded the branded product’s commercial position.
- No reliable public source reports standalone LO/Ovral-28 revenue.
- Pfizer’s 2012 packaging-related recall created temporary supply and reputational pressure but was not a patent dispute.
- The product has no biosimilar exposure because it is a conventional small-molecule tablet.
- Current Paragraph IV, Orange Book, formulation-patent, and litigation risks appear low.
- The product’s financial trajectory was a standard mature-brand decline followed by generic substitution and likely commercial withdrawal.
- Any value today would depend on a new formulation, delivery platform, indication, or distribution strategy rather than the legacy LO/Ovral-28 asset.
FAQs about LO/Ovral-28
Is LO/Ovral-28 still manufactured?
Public product records indicate a legacy or discontinued commercial position rather than an active branded franchise. Generic norgestrel/ethinyl estradiol products may remain available intermittently, depending on manufacturer and supply conditions.
Is Cryselle-28 the same as LO/Ovral-28?
Cryselle-28 contains the same stated active ingredients and strengths as LO/Ovral-28: norgestrel 0.3 mg and ethinyl estradiol 0.03 mg. Inactive ingredients, packaging, manufacturer, and availability may differ.
Can LO/Ovral-28 be relaunched with patent protection?
A relaunch of the old tablet would not restore expired exclusivity. New protection would require a patentable innovation, such as a novel formulation, delivery system, manufacturing process, or clinically differentiated use.
Did Pfizer acquire LO/Ovral-28?
Pfizer acquired Wyeth in 2009. LO/Ovral-28 was therefore associated with Pfizer’s post-acquisition product portfolio, although product ownership, manufacturing, and distribution arrangements can vary over time.
Is LO/Ovral-28 a high-value licensing asset?
No. The legacy product has low apparent licensing value because its active ingredients and conventional formulation are mature, generic competition is established, and no current patent barrier or product-level revenue stream is publicly evident.
References
-
Pfizer Inc. (2012). Recall of certain lots of LO/Ovral-28 and generic norgestrel and ethinyl estradiol tablets. Pfizer.
-
U.S. Food and Drug Administration. (2012). Drug safety communication: Voluntary recall of birth control pills due to packaging issue. FDA.
-
U.S. Food and Drug Administration. (n.d.-a). LO/Ovral-28 prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Pfizer Inc. (2009). Pfizer completes acquisition of Wyeth. Pfizer investor and corporate materials.
